- Home
- BZAI vs IOVA Comparison
BZAI vs IOVA Comparison
Compare BZAI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAI
- IOVA
- Stock Information
- Founded
- BZAI 2010
- IOVA 2007
- Country
- BZAI United States
- IOVA United States
- Employees
- BZAI N/A
- IOVA N/A
- Industry
- BZAI
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BZAI
- IOVA Health Care
- Exchange
- BZAI Nasdaq
- IOVA Nasdaq
- Market Cap
- BZAI 684.9M
- IOVA 597.7M
- IPO Year
- BZAI N/A
- IOVA N/A
- Fundamental
- Price
- BZAI $2.00
- IOVA $1.76
- Analyst Decision
- BZAI Buy
- IOVA Buy
- Analyst Count
- BZAI 2
- IOVA 10
- Target Price
- BZAI $6.50
- IOVA $12.22
- AVG Volume (30 Days)
- BZAI 345.5K
- IOVA 19.7M
- Earning Date
- BZAI 05-14-2025
- IOVA 05-08-2025
- Dividend Yield
- BZAI N/A
- IOVA N/A
- EPS Growth
- BZAI N/A
- IOVA N/A
- EPS
- BZAI N/A
- IOVA N/A
- Revenue
- BZAI $2,012,000.00
- IOVA $212,679,000.00
- Revenue This Year
- BZAI $2,062.29
- IOVA $83.64
- Revenue Next Year
- BZAI $291.44
- IOVA $70.34
- P/E Ratio
- BZAI N/A
- IOVA N/A
- Revenue Growth
- BZAI N/A
- IOVA 11070.12
- 52 Week Low
- BZAI $1.70
- IOVA $1.64
- 52 Week High
- BZAI $29.61
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- BZAI N/A
- IOVA 34.63
- Support Level
- BZAI N/A
- IOVA $1.71
- Resistance Level
- BZAI N/A
- IOVA $1.87
- Average True Range (ATR)
- BZAI 0.00
- IOVA 0.13
- MACD
- BZAI 0.00
- IOVA 0.03
- Stochastic Oscillator
- BZAI 0.00
- IOVA 41.00
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized,programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company offers semiconductor and software technology company dedicated to revolutionizing the world of AI.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.